4//SEC Filing
King Michael 4
Accession 0000950170-23-058894
CIK 0001833214other
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 4:50 PM ET
Size
6.0 KB
Accession
0000950170-23-058894
Insider Transaction Report
Form 4
King Michael
CHIEF FINANCIAL OFFICER
Transactions
- Award
Employee Stock Option (right to buy)
2023-10-30+850,000→ 850,000 totalExercise: $0.80Exp: 2033-10-30→ Common Stock (850,000 underlying)
Footnotes (2)
- [F1]Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023.
- [F2]The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (October 30, 2024), and the remainder vesting thereafter in equal monthly installments over a three year period.
Documents
Issuer
SAB Biotherapeutics, Inc.
CIK 0001833214
Entity typeother
Related Parties
1- filerCIK 0001998530
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 8:00 PM ET
- Accepted
- Nov 3, 4:50 PM ET
- Size
- 6.0 KB